What does Aalst Pharma do?

Aalst Pharma is a pharmacy in Aalst. Private Limited, started on 19 July 1991, 1 establishment.

What is the address of Aalst Pharma?

The registered office of Aalst Pharma is located at Gentse steenweg 49, 9300 Aalst.

Is Aalst Pharma still active?

Yes. According to the CBE (29 October 2026) Aalst Pharma is active, legal situation “Normale toestand”, started on 19 July 1991.

Is Aalst Pharma registered on Peppol?

Yes, Aalst Pharma is registered on the Peppol network with ID 0208:0444748067.

What is the enterprise number of Aalst Pharma?

The enterprise number of Aalst Pharma is BE0444748067.

When was Aalst Pharma founded?

Aalst Pharma was founded on 19 July 1991.

Who are the directors of Aalst Pharma?

According to the 2025 annual accounts, the directors of Aalst Pharma are: Pg Pharmaceuticals BV, Pieter Vermeersch.

Is Aalst Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 July 1991; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Aalst Pharma make in 2025?

Aalst Pharma posted a profit after taxes of € 54,034 in financial year 2025.

What is the revenue of Aalst Pharma?

As a small company, Aalst Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 170,570.

How much does an employee at Aalst Pharma earn?

The average wage cost per full-time employee at Aalst Pharma was € 59,700 in 2025: staff costs of € 83,534 for 1.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Aalst Pharma have?

According to the 2025 annual accounts, Aalst Pharma has 1.4 full-time equivalents (FTE).

Does Aalst Pharma have a website?

Yes, Aalst Pharma has a website at aalstpharma.be.

Aalst Pharma (Private Limited) - Aalst - BE0444748067

Dossier Aalst Pharma, printed on 29 October 2026 from databakkes.be/en/0444748067/aalst-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 36 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Aalst Pharma from Aalst, company number BE0444748067, closed financial year 2025 with a result of € 54,034 after tax. For that financial year Aalst Pharma recorded a gross margin of € 170,570 and equity of € 74,844. Compared with financial year 2024, the result moved from € 45,488 to € 54,034. Profitable, and profit is growing. The buffer shrank hard: equity is 66 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2026.

What it is worth Shrank hard

€ 74,844

▼ 66% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 54,034

▲ 19% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 21,736

▼ 69% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 200,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.4

▲ 0.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 83,534

▲ 242% vs 2024

€ 59,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,085

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 19 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 414,142

€ 14,135 is repaid this year. At this pace the long-term loan is gone in ≈ 19 years.

Owed to suppliers

€ 70,355

▼ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 10,013

▲ 145% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 166,649 Gross margin 2022: € 166,649 First fiscal year in the series	€ 178,843 Gross margin 2023: € 178,843 ▲ 7% vs 2022 (€ 166,649) Favourable step	€ 73,495 Gross margin 2024: € 73,495 ▼ 59% vs 2023 (€ 178,843) Unfavourable step	€ 170,570 Gross margin 2025: € 170,570 ▲ 132% vs 2024 (€ 73,495) Favourable step	▲ 132%
Profit after taxes	€ 143,648 Profit after taxes 2022: € 143,648 First fiscal year in the series	€ 155,424 Profit after taxes 2023: € 155,424 ▲ 8% vs 2022 (€ 143,648) Favourable step	€ 45,488 Profit after taxes 2024: € 45,488 ▼ 71% vs 2023 (€ 155,424) Unfavourable step	€ 54,034 Profit after taxes 2025: € 54,034 ▲ 19% vs 2024 (€ 45,488) Favourable step	▲ 19%
Equity	€ 220,097 Equity 2022: € 220,097 First fiscal year in the series	€ 220,321 Equity 2023: € 220,321 Unchanged (€ 220,097) Favourable step	€ 220,810 Equity 2024: € 220,810 Unchanged (€ 220,321) Favourable step	€ 74,844 Equity 2025: € 74,844 ▼ 66% vs 2024 (€ 220,810) Unfavourable step	▼ 66%
Total debts	€ 272,553 Total debts 2022: € 272,553 First fiscal year in the series	€ 206,203 Total debts 2023: € 206,203 ▼ 24% vs 2022 (€ 272,553) Favourable step	€ 137,999 Total debts 2024: € 137,999 ▼ 33% vs 2023 (€ 206,203) Favourable step	€ 705,764 Total debts 2025: € 705,764 ▲ € 567,764 vs 2024 (€ 137,999) Unfavourable step	▲ € 567,764
Cash	€ 254,883 Cash 2022: € 254,883 First fiscal year in the series	€ 258,136 Cash 2023: € 258,136 ▲ 1% vs 2022 (€ 254,883) Favourable step	€ 70,866 Cash 2024: € 70,866 ▼ 73% vs 2023 (€ 258,136) Unfavourable step	€ 21,736 Cash 2025: € 21,736 ▼ 69% vs 2024 (€ 70,866) Unfavourable step	▼ 69%
Land & buildings	-	-	-	€ 288,972 Land & buildings 2025: € 288,972 First fiscal year in the series
Retained profit	€ 201,505 Retained profit 2022: € 201,505 First fiscal year in the series	€ 201,729 Retained profit 2023: € 201,729 Unchanged (€ 201,505) Favourable step	€ 202,218 Retained profit 2024: € 202,218 Unchanged (€ 201,729) Favourable step	€ 56,252 Retained profit 2025: € 56,252 ▼ 72% vs 2024 (€ 202,218) Unfavourable step	▼ 72%
Dividend	€ 143,500 Dividend 2022: € 143,500 First fiscal year in the series	€ 155,200 Dividend 2023: € 155,200 ▲ 8% vs 2022 (€ 143,500) Unchanged	€ 45,000 Dividend 2024: € 45,000 ▼ 71% vs 2023 (€ 155,200) Unchanged	€ 200,000 Dividend 2025: € 200,000 ▲ € 155,000 vs 2024 (€ 45,000) Unchanged	▲ € 155,000
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 414,142 Bank debt 2025: € 414,142 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 492,650 Balance sheet total 2022: € 492,650 First fiscal year in the series	€ 426,525 Balance sheet total 2023: € 426,525 ▼ 13% vs 2022 (€ 492,650) Unchanged	€ 358,809 Balance sheet total 2024: € 358,809 ▼ 16% vs 2023 (€ 426,525) Unchanged	€ 780,607 Balance sheet total 2025: € 780,607 ▲ 118% vs 2024 (€ 358,809) Unchanged	▲ 118%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	0.5 Employees (FTE) 2023: 0.5 Unchanged (0.5) Unchanged	0.6 Employees (FTE) 2024: 0.6 ▲ 0.1 vs 2023 (0.5) Unchanged	1.4 Employees (FTE) 2025: 1.4 ▲ 0.8 vs 2024 (0.6) Unchanged	▲ 0.8

Key figures of Aalst Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Aalst Pharma?

What happened at Aalst Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 13, 2026 New annual accounts for financial year 2025: profit of € 54,034 (▲ 19% vs 2024). filed late Source: NBB ↗
2024 Pg Pharmaceuticals BV became a director. NBB
2024 Pieter Vermeersch became a director. NBB
Aug 22, 1991 New establishment in Aalst. KBO
Jul 19, 1991 Start of the company according to the CBE. KBO

In short

From € 143,648 profit in 2022 to € 54,034 profit in 2025.

Paid € 4,665 in corporate taxes since 2022.

Best year ever: 2023, with € 155,424 profit.

On average € 121,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMAFIN 100%

PG Pharmaceuticals 100%

The stake of PHARMAFIN, PG Pharmaceuticals comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Aalst Pharma

Behind Aalst Pharma are Pg Pharmaceuticals BV and Pieter Vermeersch. The shares are held by PHARMAFIN (100%) and PG Pharmaceuticals (100%).

Directors

According to the 2025 annual accounts

Pg Pharmaceuticals BV

Director

since 2024

Pieter Vermeersch

Vast vertegenwoordiger rechtspersoon

Also active at: ONE STOP MEDICAL SHOP, PG Pharmaceuticals, PV Invest Pharma

since 2024

Shareholders

PHARMAFIN

100%

PG Pharmaceuticals

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Gentse steenweg 49

9300 Aalst

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS aalstpharma.be

Technologies

BootstrapChart.jsCloudflare CDNDiviElementorFacebook PixelFont AwesomeGoogle FontsOwl CarouselPHPSwiperWP RocketWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizesreCAPTCHA

Hosting & Email

Email provider

Self-hosted

Hosting

CLOUDFLARENET - Cloudflare, Inc., US

DNS

Cloudflare DNS

Website info

HTTPS Ja

Languages NL

Features

Webshop Blog Ads Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

✓ Load balancing

Details

Company number

0444.748.067

VAT number

BE 0444.748.067

Registered office

Gentse steenweg 49, 9300 Aalst

Names & denominations

Aalst Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

19 July 1991

Peppol

Active · Active since 1 Jan 2001

Contact

aalstpharma.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Aalst Pharma

Warning lights

Financials

What happened to Aalst Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions